Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non Operating Income: 2017-2024

Historic Other Non Operating Income for Aclaris Therapeutics (ACRS) over the last 7 years, with Jun 2024 value amounting to $1.9 million.

  • Aclaris Therapeutics' Other Non Operating Income fell 16.83% to $1.9 million in Q2 2024 from the same period last year, while for Jun 2024 it was $8.4 million, marking a year-over-year increase of 31.29%. This contributed to the annual value of $8.5 million for FY2023, which is 188.83% up from last year.
  • As of Q2 2024, Aclaris Therapeutics' Other Non Operating Income stood at $1.9 million, which was down 6.13% from $2.0 million recorded in Q1 2024.
  • Aclaris Therapeutics' 5-year Other Non Operating Income high stood at $2.3 million for Q3 2023, and its period low was -$851,000 during Q3 2021.
  • Moreover, its 3-year median value for Other Non Operating Income was $1.8 million (2023), whereas its average is $1.5 million.
  • In the last 5 years, Aclaris Therapeutics' Other Non Operating Income slumped by 338.66% in 2021 and then surged by 1,522.47% in 2022.
  • Aclaris Therapeutics' Other Non Operating Income (Quarterly) stood at -$219,000 in 2020, then surged by 140.64% to $89,000 in 2021, then soared by 1,522.47% to $1.4 million in 2022, then skyrocketed by 51.59% to $2.2 million in 2023, then fell by 16.83% to $1.9 million in 2024.
  • Its Other Non Operating Income was $1.9 million in Q2 2024, compared to $2.0 million in Q1 2024 and $2.2 million in Q4 2023.